Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome

C. M. Legendre, C. Licht, P. Muus, L. A. Greenbaum, S. Babu, C. Bedrosian C Bingham, D. J. Cohen, Y. Delmas, K. Douglas, F. Eitner, T. Feldkamp, D. Fouque, R. R. Furman, O. Gaber, M. Herthelius, M. Hourmant, D. Karpman, Y. Lebranchu, C. Mariat, J. MenneB. Moulin, J. Nürnberger, M. Ogawa, G. Remuzzi, T. Richard, R. Sberro-Soussan, B. Severino, N. S. Sheerin, A. Trivelli, L. B. Zimmerhackl, T. Goodship, C. Loirat

Research output: Contribution to journal › Article › peer-review

1053 Scopus citations

Fingerprint

Dive into the research topics of 'Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome'. Together they form a unique fingerprint.

Medicine & Life Sciences